Breast cancer is caused due to uncontrolled growth of cells in breast area. Lumps or tumors are formed due to the growth of cells in the tissues surrounding the breast. If a lump is malignant then cancer can spread to other parts of the body. The risk of breast cancer is high amongst women due to many reasons like hormonal imbalances cause during menopause, irregular menstrual cycle, and obesity. However, even men are also prone to contract breast cancer. Breast cells get cancerous mainly due to mutations in DNA. The breast cancer therapeutics market is expected to observe prominent growth prospects due to increase in demand for breast cancer treatment therapies on a large scale.
According to the statistics, many studies breast cancer is the second largest cause of deaths across the world. The number of breast cancer patients is increasing at an alarming rate. This factor has given rise to the need of efficient therapies to treat and cure breast cancer, which in turn, is boosting the expansion of the breast cancer therapeutics market.
A fast-paced urban lifestyle has led to increase in work stress. In addition, sedentary lifestyle of people has given rise to various health issues. These aspects have increased the prevalence of breast cancer, which will have a positive impact on the growth of the breast cancer therapeutics market. Lack of exercise, overstressed routine life, and negligence towards health concerns have resulted in increased cases of breast cancer. The health condition can be cured if it is diagnosed and treated at earlier stage. Taking all these factors into consideration, the demand for breast cancer therapeutics has accelerated the growth of the global breast cancer therapeutics market.
The existence of large number of breast cancer patients worldwide has increased the need for effective screening, diagnosis, and treatment. The awareness among the masses regarding breast cancer is increasing and this has augmented the sales of various cancer treatment drugs and therapies, eventually adding value to the growth of the breast cancer therapeutics market. Many key players in the breast cancer therapeutics market are investing in R&D activities to initiate new therapeutics and treatment methods to treat breast cancer.
Changing Lifestyles Necessitate Change in Game Plan of Breast Cancer Therapeutics Providers
The changing lifestyles and the growing issue of obesity have heightened the risk of breast cancer amongst women in recent years. Statistics indicate that breast cancer has become the second largest cause of fatalities across the globe. Thus, the increasing number initiatives to raise awareness about this deadly disease and treat patients for this disease has boosted the global breast cancer therapeutics market. The increasing awareness amongst patients about the disease and improving accessibility to premium treatments has also augmented the sales of various drugs in this market. Effective research and development for new treatments to efficiently treat breast cancer is also expected to change the game for this market.
Transparency Market Research forecasts that the global breast cancer therapeutics market is expected to be worth US$16.21 bn by 2023 as compared to US$7.17 bn in 2014, surging at a CAGR of 8.4% between 2015 and 2023. The drastically changing reproductive patterns are also responsible for soaring revenue earnings of the breast cancer therapeutics market. The delayed childbearing age, reduced breastfeeding periods, intake of oral contraceptives, and resorting to hormonal therapies to solve other medical conditions is also contributing towards the growth of this market.
Higher Percentage of Survivors in North America Puts Region in the Lead
A study conducted by World Cancer Research Fund International (WCRF) stated that North America has the highest percentage of breast cancer survivors after diagnoses, while it is the lowest in the developing countries of Asia and Africa. However, breast cancer continues to be a serious health concern in South America, Africa, and Asia.
WRCF also states that North America has a high incidence of breast cancer, however, the breast cancer therapeutics market is progressing in this region due to supportive insurance schemes meted by the government. The overall North America breast cancer therapeutics market is expected to surge at 7.3% CAGR between 2015 and 2023 during the forecast period. The risks of post-treatment complications and relapse are the only two key factors hampering this regional market.
Accurate Diagnosis through HER2 Inhibitors Increases Preference for the Drug Class
Amongst the various drug classes, the HER2 inhibitors segment was the leading segment in 2014. During the forecast period, the HER2 inhibitors segment is expected to expand at a CAGR of 6.2% due to their ability to deliver accurate diagnostics. HER2 inhibitors are used in case of metastatic breast cancer (MBC) patients who have undergone a minimum of two chemotherapeutic schedules of taxane and anthracycline. All of these factors are expected to raise the market opportunity of the HER2 inhibitors segment to a significant amount by the end of forecast period.
The key players operating in the global breast cancer therapeutics market are GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Puma Biotechnology, Novartis International AG, and Sanofi S.A. Companies are focusing on research and development to launch new products along with acquiring small companies to improve the existing line of products. However, these companies are governed by strict regulatory framework, which often causes delay in launching products.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure Report (PDF) sent to your email within minutes
Breast cancer therapeutics market is expected to be worth US$16.21 bn by 2023
Breast cancer therapeutics market to Expand at a CAGR of 8.4% between 2015 and 2023
Breast cancer therapeutics market is driven by increasing awareness amongst patients about the disease and improving accessibility to premium treatments
North America accounted for a major share of the global breast cancer therapeutics market
Key players in the global breast cancer therapeutics market are GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Pfizer, Inc., F. Hoffmann-La Roche Ltd.
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
2 Executive Summary
2.1 Global Breast Cancer Therapeutics: Market Snapshot
2.2 Global Breast Cancer Therapeutics Market Share, by Geography, 2014 & 2023(Value %)
2.3 Global Breast Cancer Therapeutics Market, by Drug Class, 2014 & 2023 (Value %)
3 Global Breast Cancer Therapeutics Market - Market Overview
3.1 Market Definition and Overview
3.2 Epidemiology & High Risk Groups
3.3 Diagnosis and Types of Breast Cancer
3.4 Other Breast Cancer Therapies
3.5 Market Dynamics
18.104.22.168 Higher Incidence Rate
22.214.171.124 Demographic Transition
126.96.36.199 Rising Prevalence Of Obesity
188.8.131.52 Diagnostic Screening Programs
184.108.40.206 Increase in Private Health Insurance Plans:
220.127.116.11 Generic Drugs: Substitute Branded Drugs
18.104.22.168 Intense Competition: Fall in Prices
22.214.171.124 Access barriers due to high drug costs
126.96.36.199 Absence of Social Health Insurance
188.8.131.52 Serious Side Effects of Breast Cancer Therapeutics
184.108.40.206 Countries Lacking Women Empowerment
220.127.116.11 Newer medication options
18.104.22.168 Potential Growth of Domestic Pharmaceutical Companies
22.214.171.124 Combination Drug Therapy
126.96.36.199 Technological Advancements and Robust Trends of Drug Approval
188.8.131.52 New Companion Diagnostics Models
184.108.40.206 Drug Therapy for Triple Negative (TNBC)
220.127.116.11 Approval for Multiple Indications (positive & negative types) HER2 breast cancer
3.7 Market Attractiveness Analysis– Breast Cancer Therapeutics Market, by Geography (2014) (%)
3.8 Competitive Landscape – Breast Cancer Therapeutics Market, by Key Players, 2014 (%)
4 Market Segmentation – By Drug Class
4.2 Global HER2 Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.2.1 Herceptin (Trastuzumab)
4.2.2 Tykerb (Lapatinib)
4.2.3 Perjeta (Pertuzumab)
4.2.4 Kadcyla (Ado-trastuzumab emtansine)
4.3 Global Mitotic Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.3.1 Halaven (Eribulin)
4.3.2 Taxotere (Docetaxel)
4.3.3 Ixempra (Ixabepilone)
4.4 Global Anti-metabolites Market Revenue, 2015–2023 (US$ Mn)
4.4.1 Gemzar (Gemcitabine)
4.5 Global Aromatase Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.5.1 Femara (Leterozole)
4.5.2 Aromasin (Exemestane)
4.5.3 Arimidex (Anastrozole)
4.5.4 Ibrance (Palbociclib)
4.5.5 Afinitor (Everolimus)
4.6 Global Hormone Receptor Market Revenue, 2015–2023 (US$ Mn)
5 Market Segmentation – By Geography
5.2 Global Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.3 North America Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.4 Europe Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.4.4 Rest of Europe
5.5 Asia Pacific Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.5.2 South Korea
5.5.3 Rest of Asia Pacific
5.6 Rest of the World
5.6.1 Latin America
18.104.22.168 Rest of Latin America
5.6.2 Middle East and Africa
7 Company Profiles
7.1 AstraZeneca plc
7.2 Eisai Co., Ltd.
7.3 Eli Lilly and Company
7.4 F. Hoffmann-La Roche Ltd.
7.5 GlaxoSmithKline plc
7.6 Novartis International AG
7.7 Pfizer, Inc.
7.8 Puma Biotechnology, Inc.
7.9 Sanofi S.A.
7.10 Teva Pharmaceutical Industries Ltd.
Complete the form below and we'll get back to you shortly.